EA201990762A1 - METHODS FOR TREATING FEMALE INFERTILITY - Google Patents

METHODS FOR TREATING FEMALE INFERTILITY

Info

Publication number
EA201990762A1
EA201990762A1 EA201990762A EA201990762A EA201990762A1 EA 201990762 A1 EA201990762 A1 EA 201990762A1 EA 201990762 A EA201990762 A EA 201990762A EA 201990762 A EA201990762 A EA 201990762A EA 201990762 A1 EA201990762 A1 EA 201990762A1
Authority
EA
Eurasian Patent Office
Prior art keywords
methods
provides
female infertility
treating female
pregnancy
Prior art date
Application number
EA201990762A
Other languages
Russian (ru)
Inventor
Виджайкумар Редди Раджашекхар
Брендан Марк Джонсон
Лора Энн Уилльямс
Original Assignee
Миовант Саенсис Гмбх
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Миовант Саенсис Гмбх filed Critical Миовант Саенсис Гмбх
Priority claimed from PCT/EP2017/074800 external-priority patent/WO2018060438A1/en
Publication of EA201990762A1 publication Critical patent/EA201990762A1/en

Links

Abstract

Дополнительно, в соответствии с данным изобретением, предусматриваются способы промотирования созревания яйцеклетки во вспомогательных репродуктивных технологиях, таких как in vitro оплодотворение (ЭКО) или в процессе переноса эмбриона (ПЭ). Также предусматриваются способы снижения частоты синдрома гиперстимуляции яичников (СГЯ), что обеспечивает сопоставимую или повышенную частоту наступления беременности, уменьшает время до наступления беременности и ингибирует преждевременную овуляцию. Указанные способы включают стадию введения терапевтически эффективного количества активного фармацевтического ингредиента 2-(N-ацетил-D-тирозил-транс-4-гидрокси-L-пролил-L-аспарагинил-L-треонил-L-фенилаланил)гидразинокарбонил-L-лейцил-Nro-метил-L-аргинил-L-триптофанамида или его фармацевтически приемлемой соли.Additionally, in accordance with this invention, methods are provided for promoting egg maturation in assisted reproductive technologies such as in vitro fertilization (IVF) or during embryo transfer (PE). It also provides methods to reduce the frequency of ovarian hyperstimulation syndrome (OHSS), which provides a comparable or increased pregnancy rate, reduces the time before pregnancy and inhibits premature ovulation. These methods include the step of administering a therapeutically effective amount of the active pharmaceutical ingredient 2- (N-acetyl-D-tyrosyl-trans-4-hydroxy-L-prolyl-L-asparaginyl-L-threonyl-L-phenylalanyl) hydrazinocarbonyl-L-leucyl- Nro-methyl-L-arginyl-L-tryptophanamide or a pharmaceutically acceptable salt thereof.

EA201990762A 2016-09-30 2017-09-29 METHODS FOR TREATING FEMALE INFERTILITY EA201990762A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662402018P 2016-09-30 2016-09-30
PCT/EP2017/074800 WO2018060438A1 (en) 2016-09-30 2017-09-29 Methods of treating female infertility

Publications (1)

Publication Number Publication Date
EA201990762A1 true EA201990762A1 (en) 2019-12-30

Family

ID=66326333

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201990762A EA201990762A1 (en) 2016-09-30 2017-09-29 METHODS FOR TREATING FEMALE INFERTILITY

Country Status (2)

Country Link
AR (1) AR110636A1 (en)
EA (1) EA201990762A1 (en)

Also Published As

Publication number Publication date
AR110636A1 (en) 2019-04-17

Similar Documents

Publication Publication Date Title
ZA202202097B (en) Amino pyrimidine ssao inhibitors
MX2021004110A (en) Pharmaceutical compositions comprising n-(3,5-dimethoxyphenyl)-n' -(1-methylethyl)-n-[3-(1-methyl-1h-pyrazol-4-yl)quinoxalin-6-yl] ethane-1,2-diamine.
EA201890725A1 (en) PHARNESIDE X-RECEPTOR AGONISTS AND THEIR APPLICATION
EA201790078A1 (en) MNK INHIBITORS AND RELATED METHODS
MX2019009501A (en) Amino pyrimidine compounds useful as ssao inhibitors.
TR201901312T4 (en) Tetrahydronaphthalene derivatives that inhibit the Mcl-1 protein.
PH12020550256A1 (en) 1-benzyl-2-imino-4-phenyl-5-oxoimidazolidine derivatives as hiv protease inhibitors
MX2023002507A (en) Cd73 inhibitors.
MX2021002321A (en) Novel methods.
MX2019008875A (en) Crac channel inhibitor compositions.
MX2017009417A (en) Solid forms of 2-(5-(3-fluorophenyl)-3-hydroxypicolinamido)acetic acid, compositions, and uses thereof.
CL2018001830A1 (en) Formulations of 2- (4-chlorophenyl) -n - ((2- (2,6-dioxopiperidin-3-yl) -1-oxoisoindolin-5-yl) methyl) -2,2-difluoroacetamide
PH12019502150A1 (en) Compounds and methods for the treatment of parasitic diseases
CL2019002325A1 (en) Pharmaceutical combinations to treat cancer.
CR20210480A (en) Pharmaceutical formulations
AU2024202380A1 (en) Methods of preventing or treating ophthalmic diseases
MX2021002322A (en) Novel methods.
MX2018015353A (en) Therapeutic uses of a c-raf inhibitor.
EA035519B9 (en) 1,3,4-thiadiazole compounds and their use in treating cancer
EA202090164A1 (en) Isotretinoin oral-mucous compositions and methods for their use
EA201990762A1 (en) METHODS FOR TREATING FEMALE INFERTILITY
MX2019015280A (en) Statin compositions and methods for use in treating synucleinopathies.
EA202090346A1 (en) METHOD FOR PREPARING N - ((1R, 2S, 5R) -5- (TET-BUTYLAMINO) -2 - ((S) -3- (7-TET-BUTYLPYRAZOLO [1,5-a] [1,3,5] TRIAZIN-4-ILAMINO) -2-OXOPYRROLIDIN-1-YL) CYCLOHEXYL) ACETAMIDE
MX2018012952A (en) Ophthalmic composition comprising a synergistic combination of glycogen and hyaluronic acid or a salt thereof.
CL2019002239A1 (en) Pediatric Cancer Treatment Methods. (divisional request 201802807)